About Becton Dickinson and (NYSE:BDX)
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
Industry, Sector and Symbol
Industry MED PRODS
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio160.763358778626
Forward P/E Ratio19.23
Sales & Book Value
Annual Sales$12.09 billion
Price / Sales4.64
Cash Flow$13.93 per share
Price / Cash15.12
Book Value$56.89 per share
Price / Book3.70
Net Income$1.10 billion
Return on Equity16.19%
Return on Assets5.74%
Becton Dickinson and (NYSE:BDX) Frequently Asked Questions
What is Becton Dickinson and's stock symbol?
Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."
How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?
Becton Dickinson and announced a quarterly dividend on Monday, January 22nd. Investors of record on Friday, March 9th will be paid a dividend of $0.75 per share on Friday, March 30th. This represents a $3.00 annualized dividend and a dividend yield of 1.42%. The ex-dividend date of this dividend is Thursday, March 8th. View Becton Dickinson and's Dividend History.
How were Becton Dickinson and's earnings last quarter?
Becton Dickinson and Co (NYSE:BDX) announced its quarterly earnings data on Tuesday, February, 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Zacks' consensus estimate of $2.41 by $0.07. The medical instruments supplier had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.33 EPS. View Becton Dickinson and's Earnings History.
When will Becton Dickinson and make its next earnings announcement?
What guidance has Becton Dickinson and issued on next quarter's earnings?
Becton Dickinson and issued an update on its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $10.85-11.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.88.
Where is Becton Dickinson and's stock going? Where will Becton Dickinson and's stock price be in 2018?
16 equities research analysts have issued 1 year target prices for Becton Dickinson and's stock. Their forecasts range from $180.00 to $260.00. On average, they anticipate Becton Dickinson and's share price to reach $236.60 in the next twelve months. View Analyst Ratings for Becton Dickinson and.
Who are some of Becton Dickinson and's key competitors?
Some companies that are related to Becton Dickinson and include Abbott Laboratories (ABT), Medtronic (MDT), Thermo Fisher Scientific (TMO), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Fresenius Medical Care AG & Co. (FMS), McKesson (MCK), Essilor International (ESLOY), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), Sunny Optical Tech (SNPTF), Align Technology (ALGN), Cardinal Health (CAH), AmerisourceBergen (ABC), Lonza Group (LZAGY) and IDEXX Laboratories (IDXX).
Who are Becton Dickinson and's key executives?
Becton Dickinson and's management team includes the folowing people:
- Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer (Age 64)
- Thomas E. Polen, President (Age 44)
- Christopher R. Reidy, Chief Financial Officer, Executive Vice President, Chief Administrative Officer (Age 60)
- Linda M. Tharby, Chief Human Resource Officer, Executive Vice President (Age 49)
- Nabil Shabshab, Executive Vice President - Strategic Planning Chief Marketing Officer (Age 52)
- Alexandre Conroy, Executive Vice President and President, Europe, EMA (Age 54)
- James Lim, Executive Vice President and President, Greater Asia (Age 53)
- Alberto Mas, Executive Vice President and President - Life Sciences Segment (Age 56)
- Catherine M. Burzik, Independent Director (Age 67)
- R. Andrew Eckert, Independent Director (Age 56)
Has Becton Dickinson and been receiving favorable news coverage?
Media stories about BDX stock have been trending somewhat negative on Saturday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Becton Dickinson and earned a media sentiment score of -0.02 on Accern's scale. They also gave news stories about the medical instruments supplier an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Becton Dickinson and's major shareholders?
Becton Dickinson and's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.07%), Franklin Resources Inc. (1.39%), Geode Capital Management LLC (0.83%), Jensen Investment Management Inc. (0.82%), Renaissance Technologies LLC (0.78%) and Bank of New York Mellon Corp (0.76%). Company insiders that own Becton Dickinson and stock include Ellen R Strahlman, Gary M Cohen, James C Lim, James F Orr, James W Borzi, Jeffrey S Sherman, Jerome V Hurwitz, John E Gallagher, Linda M Tharby, Nabil Shabshab, Rebecca W Rimel, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr, Timothy M Ring and Vincent A Forlenza. View Institutional Ownership Trends for Becton Dickinson and.
Which major investors are selling Becton Dickinson and stock?
BDX stock was sold by a variety of institutional investors in the last quarter, including Generation Investment Management LLP, Winslow Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Sei Investments Co., Jensen Investment Management Inc., Cooke & Bieler LP, British Airways Pensions Investment Management Ltd and Mawer Investment Management Ltd.. Company insiders that have sold Becton Dickinson and company stock in the last year include Ellen R Strahlman, Gary M Cohen, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Insider Buying and Selling for Becton Dickinson and.
Which major investors are buying Becton Dickinson and stock?
BDX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Amundi Pioneer Asset Management Inc., Gardner Lewis Asset Management L P, HBK Investments L P, TIAA CREF Investment Management LLC, Alpine Associates Management Inc. and Mackenzie Financial Corp. View Insider Buying and Selling for Becton Dickinson and.
How do I buy shares of Becton Dickinson and?
Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Becton Dickinson and's stock price today?
One share of BDX stock can currently be purchased for approximately $210.60.
How big of a company is Becton Dickinson and?
Becton Dickinson and has a market capitalization of $56.78 billion and generates $12.09 billion in revenue each year. The medical instruments supplier earns $1.10 billion in net income (profit) each year or $1.31 on an earnings per share basis. Becton Dickinson and employs 41,933 workers across the globe.
How can I contact Becton Dickinson and?
Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.
MarketBeat Community Rating for Becton Dickinson and (BDX)MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Becton Dickinson and (NYSE:BDX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.80||2.77||2.79|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$236.60||$235.71||$217.15||$199.54|
|Price Target Upside: ||12.35% upside||4.68% upside||0.82% downside||4.16% upside|
Becton Dickinson and (NYSE:BDX) Consensus Price Target History
Becton Dickinson and (NYSE:BDX) Analyst Ratings History
(Data available from 3/24/2016 forward)
Becton Dickinson and (NYSE:BDX) Earnings History and Estimates Chart
Becton Dickinson and (NYSE BDX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/6/2018||Q1 2018||$2.41||$2.48||$3.05 billion||$3.08 billion||View||Listen|
|11/2/2017||Q4 2017||$2.37||$2.40||$3.14 billion||$3.17 billion||View||N/A|
|8/3/2017||Q3 2017||$2.44||$2.46||$3.06 billion||$3.04 billion||View||Listen|
|5/2/2017||Q2 2017||$2.23||$2.30||$2.92 billion||$2.97 billion||View||Listen|
|2/2/2017||Q117||$2.11||$2.33||$2.86 billion||$2.92 billion||View||Listen|
|11/3/2016||Q416||$2.09||$2.12||$3.22 billion||$3.23 billion||View||Listen|
|8/4/2016||Q316||$2.20||$2.35||$3.21 billion||$3.20 billion||View||Listen|
|5/5/2016||Q216||$2.02||$2.18||$3.07 billion||$3.07 billion||View||Listen|
|2/3/2016||Q116||$1.84||$1.96||$3.04 billion||$2.99 billion||View||Listen|
|11/4/2015||Q415||$1.90||$1.94||$3.04 billion||$3.07 billion||View||Listen|
|8/6/2015||Q315||$2.01||$2.05||$3.13 billion||$3.12 billion||View||Listen|
|5/7/2015||Q2||$1.54||$1.61||$2.05 billion||$2.05 billion||View||Listen|
|2/5/2015||Q115||$1.43||$1.53||$2.04 billion||$2.05 billion||View||Listen|
|11/4/2014||Q414||$1.65||$1.68||$2.16 billion||$2.20 billion||View||Listen|
|7/31/2014||Q314||$1.68||$1.68||$2.14 billion||$2.16 billion||View||Listen|
|5/1/2014||Q2||$1.50||$1.53||$2.09 billion||$2.07 billion||View||Listen|
|2/4/2014||Q114||$1.30||$1.42||$1.98 billion||$2.00 billion||View||Listen|
|11/5/2013||Q413||$1.46||$1.52||$2.05 billion||$2.10 billion||View||Listen|
|8/1/2013||Q3 2013||$1.48||$1.58||$2.05 million||$2.05 billion||View||Listen|
|5/2/2013||Q2 2013||$1.35||$1.44||$1.99 billion||$2.00 billion||View||Listen|
|2/5/2013||Q1 2013||$1.24||$1.35||$1.86 billion||$1.90 billion||View||Listen|
|11/7/2012||Q412||$1.40||$1.42||$1.96 billion||$1.97 billion||View||N/A|
Becton Dickinson and (NYSE:BDX) Earnings Estimates
2018 EPS Consensus Estimate: $10.75
2019 EPS Consensus Estimate: $12.72
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Becton Dickinson and (NYSE:BDX) Dividend Information
|Dividend Growth:||9.60% (3 Year Average)|
|Payout Ratio:||229.01% (Trailing 12 Months of Earnings) |
27.40% (Based on This Year's Estimates)
23.79% (Based on Next Year's Estimates)
|Track Record:||46 Years of Consecutive Dividend Growth|
Becton Dickinson and (NYSE:BDX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Becton Dickinson and (NYSE BDX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 83.35%
Becton Dickinson and (NYSE BDX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/13/2018||Thomas E Polen Jr||EVP||Sell||1,877||$227.00||$426,079.00||15,387|| |
|2/27/2018||John E Gallagher||VP||Sell||5,346||$226.08||$1,208,623.68||9,391|| |
|2/26/2018||James W Borzi||EVP||Sell||4,048||$224.98||$910,719.04||5,334|| |
|2/23/2018||Timothy M Ring||Director||Sell||176||$218.27||$38,415.52||170,688|| |
|2/8/2018||Timothy M Ring||Director||Sell||269,661||$217.82||$58,737,559.02||295,753|| |
|9/11/2017||Gary M Cohen||Insider||Sell||15,512||$203.77||$3,160,880.24||95,781|| |
|9/8/2017||Stephen Sichak||Insider||Sell||11,787||$200.46||$2,362,822.02||14,038|| |
|8/22/2017||Gary M Cohen||Insider||Sell||15,044||$200.43||$3,015,268.92||95,270|| |
|8/22/2017||Linda M Tharby||EVP||Sell||4,695||$200.48||$941,253.60||18,670|| |
|8/15/2017||Nabil Shabshab||Insider||Sell||6,149||$201.76||$1,240,622.24||15,648|| |
|8/14/2017||Ribo Alberto Mas||EVP||Sell||7,463||$201.41||$1,503,122.83||29,323|| |
|8/10/2017||Ellen R Strahlman||Insider||Sell||9,283||$198.21||$1,839,983.43||26,638|| |
|8/9/2017||Thomas E Polen Jr||Insider||Sell||5,971||$197.41||$1,178,735.11||12,861|| |
|5/25/2017||Jeffrey S Sherman||VP||Sell||28,765||$185.98||$5,349,714.70||70,821|| |
|2/15/2017||Jeffrey S Sherman||VP||Sell||31,464||$180.02||$5,664,149.28||22,094|| |
|12/15/2016||John E Gallagher||VP||Sell||1,793||$168.82||$302,694.26||2,796|| |
|12/5/2016||Stephen Sichak||Insider||Sell||2,632||$164.44||$432,806.08||7,953|| |
|11/4/2016||Stephen Sichak||Insider||Sell||10,352||$176.10||$1,822,987.20||26,892|| |
|9/6/2016||Linda M Tharby||Insider||Sell||11,704||$177.27||$2,074,768.08||22,146|| |
|8/11/2016||Gary M Cohen||Insider||Sell||29,367||$176.81||$5,192,379.27||125,870|| |
|6/13/2016||John E Gallagher||VP||Sell||1,931||$169.87||$328,018.97||6,758|| |
|6/7/2016||Nabil Shabshab||EVP||Sell||5,080||$168.75||$857,250.00||11,092|| |
|5/17/2016||Jeffrey S Sherman||VP||Sell||34,373||$166.27||$5,715,198.71||49,736|| |
|5/13/2016||Stephen Sichak||EVP||Sell||12,995||$166.48||$2,163,407.60||31,561|| |
|5/13/2016||Vincent A Forlenza||CEO||Sell||37,933||$166.17||$6,303,326.61||207,225|| |
|5/10/2016||James F Orr||Director||Sell||1,368||$167.66||$229,358.88||23,045|| |
|5/9/2016||James C Lim||EVP||Sell||5,257||$165.60||$870,559.20||12,556|| |
|5/6/2016||Ellen R Strahlman||SVP||Sell||3,019||$163.52||$493,666.88||7,218|| |
|5/6/2016||Jerome V Hurwitz||EVP||Sell||3,878||$163.58||$634,363.24||3,027|| |
|5/6/2016||Rebecca W Rimel||Director||Sell||684||$163.69||$111,963.96||6,835|| |
|12/14/2015||Stephen Sichak||EVP||Sell||8,670||$152.21||$1,319,660.70||8,646|| |
|12/9/2015||William A Kozy||EVP||Sell||15,495||$154.43||$2,392,892.85||68,823|| |
|12/8/2015||Vincent A. Forlenza||CEO||Sell||17,762||$153.10||$2,719,362.20||172,681|| |
|12/7/2015||Jeffrey S Sherman||VP||Sell||7,586||$153.76||$1,166,423.36||23,734|| |
|12/1/2015||Thomas E Polen Jr||EVP||Sell||2,683||$152.21||$408,379.43||5,789|| |
|11/30/2015||John E Gallagher||VP||Sell||1,600||$150.70||$241,120.00||3,393|| |
|11/18/2015||Jerome V. Hurwitz||EVP||Sell||2,347||$151.02||$354,443.94||4,866|| |
|6/1/2015||Stephen Sichak||EVP||Sell||12,188||$140.94||$1,717,776.72|| |
|5/22/2015||Thomas E Polen Jr||EVP||Sell||3,882||$142.56||$553,417.92|| |
|5/21/2015||Linda M Tharby||EVP||Sell||6,069||$142.02||$861,919.38|| |
|5/20/2015||William A Kozy||EVP||Sell||10,326||$142.00||$1,466,292.00|| |
|5/19/2015||William A Kozy||EVP||Sell||10,435||$142.01||$1,481,874.35|| |
|5/18/2015||Bertram L Scott||Director||Sell||2,160||$141.74||$306,158.40|| |
|5/18/2015||James C Lim||EVP||Sell||3,604||$141.80||$511,047.20|| |
|5/15/2015||Alexandre Conroy||EVP||Sell||1,291||$141.37||$182,508.67|| |
|5/13/2015||Jeffrey S Sherman||VP||Sell||10,983||$138.40||$1,520,047.20|| |
|5/11/2015||Jerome V Hurwitz||EVP||Sell||1,197||$141.43||$169,291.71|| |
|5/8/2015||Gary M Cohen||EVP||Sell||13,490||$142.90||$1,927,721.00|| |
|6/12/2014||Stephen Sichak||SVP||Sell||1,456||$118.25||$172,172.00|| |
|6/10/2014||Gary M Cohen||EVP||Sell||12,476||$119.24||$1,487,638.24|| |
|6/9/2014||Jeffrey S Sherman||VP||Sell||7,877||$120.24||$947,130.48|| |
|3/6/2014||Jeffrey Sherman||VP||Sell||1,303||$115.16||$150,053.48||27,768|| |
|11/12/2013||William Kozy||EVP||Sell||9,597||$108.30||$1,039,355.10||101,090|| |
|11/11/2013||Jeffrey Sherman||VP||Sell||4,272||$107.78||$460,436.16||25,176|| |
|11/11/2013||Jerome Hurwitz||SVP||Sell||1,151||$107.78||$124,054.78||1,687|| |
|11/8/2013||Vincent Forlenza||CEO||Sell||32,411||$107.39||$3,480,617.29||108,724|| |
|11/6/2013||Henry Becton, Jr.||Director||Sell||2,276||$106.77||$243,008.52||23,820|| |
|8/23/2013||Bertram Scott||Director||Sell||4,047||$98.61||$399,074.67||20,768|| |
|8/8/2013||Edward Degraan||Director||Sell||4,436||$100.03||$443,733.08||18,608|| |
|8/8/2013||Stephen Sichak||SVP||Sell||3,431||$100.13||$343,546.03||6,297|| |
|8/7/2013||Basil Anderson||Director||Sell||2,160||$99.79||$215,546.40||17,221|| |
|5/22/2013||Henry P Becton Jr||Director||Sell||3,117||$101.86||$317,497.62|| |
|5/17/2013||Donna M Boles||VP||Sell||2,415||$101.38||$244,832.70|| |
|5/13/2013||Gary M Cohen||EVP||Sell||8,753||$100.22||$877,225.66|| |
Becton Dickinson and (NYSE BDX) News Headlines
Becton Dickinson and (NYSE:BDX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Becton Dickinson and (NYSE:BDX) Income Statement, Balance Sheet and Cash Flow Statement
Becton Dickinson and (NYSE BDX) Stock Chart for Saturday, March, 24, 2018